US3338902A - Esters of piperazine 1, 4-diethanol - Google Patents

Esters of piperazine 1, 4-diethanol Download PDF

Info

Publication number
US3338902A
US3338902A US412859A US41285964A US3338902A US 3338902 A US3338902 A US 3338902A US 412859 A US412859 A US 412859A US 41285964 A US41285964 A US 41285964A US 3338902 A US3338902 A US 3338902A
Authority
US
United States
Prior art keywords
acid
piperazine
compounds
hydroxyethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US412859A
Other languages
English (en)
Inventor
Pala Gianfranco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto de Angeli SpA
Original Assignee
Instituto de Angeli SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto de Angeli SpA filed Critical Instituto de Angeli SpA
Application granted granted Critical
Publication of US3338902A publication Critical patent/US3338902A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Definitions

  • This invention relates to new N,N'-di(fl-hydroxyethyl) Spasmvlytic activity guinea-Pig ileum vitro" piperazine esters of tit-substituted l-naphthyl-acetic acids.
  • the test was carried out in segments of guinea pig i to mventlon I provlde compounds of ileum according to the Magnus-Technique.
  • the intestine e genera 0mm a was stimulated with standard doses of acetylcholine (1.10- g./ml.), histamine (1.10- g./ml.), BaCl (1.10- g./ml.), nicotine (2.10 g./ml.) and serotonine (1.10- g./ml.), and then the dosage of the substances able to produce a 50% inhibition of the contractions was determined.
  • DA-914 is 203 times associated with said salts being physiologically acceptable more active than papaverine and 42 times more active at the effective dosage of the compounds. than hexamethonium bitartrate.
  • the compounds according to the invention possess pars asmolytic activity onguinea-pig ileum in vivo ticularly valuable spasmolytic activity of the myolytic
  • the test was carried out according to the method of type which is generally more pronounced than that of Brock and coll (Arch Exp Path Pharmacol 215 512 known compounds of related structure.
  • the contractions were produced, every rmin gum.ea'p1g lleilm Simulated by banum i acetyl utes, by perfusion of the peritoneum with BaCl solution F f and hlstamme' i compounds. i to the at the concentration of 10 mg./l.
  • the perfusion was of 30 mventlon also y reiatwely low.toxlclty i for 45 seconds duration and the intestinal movements were reample the m mlce. of i .dlhydmchlonflie the corded by means of a water manometer.
  • the compound a'methyu'naphthyl.
  • acetlc acld .dlester to be tested was injected, intravenously, at various dosage droxyethyl)'pl.perazl.ne by the mtrapentoneal and oral levels 75 seconds prior to the perfusion.
  • droxyethyl i and 1600 mgJkg
  • it was preferred to administer ethaverine hywhlle chrome toxlclty tests showed that .rats P drochloride rather than papaverine because of the fore.rate 50 of the above hydrochlonde wlthout mers lower toxicity.
  • the compounds according to the invention are colourin the following table, less crystalline solids.
  • the free bases are insoluble in water and soluble in alcohol whilst the acid addition salts are sparingly soluble in alcohol and very moderately Dose figggtg g of EDS, soluble in water.
  • Particularly preferred compounds acs-l a/ commotion a/ scording to the invention, by virtue of their high spasmo- 8 3 13??? lytic activity, are those compounds of Formula I in which R represents a lower alkyl group containing 1 to 3 carbon 5 36 atoms.
  • the salts according to the invention may be 1311414 5- i formed by treating the free base with an acid, for exam- 5 25 ple a hydrohalic acid such as hydrochloric or hydro- Ethaverifle Y $2 10.8 bromic acid, phosphoric acid, sulphuric acid, methane sul honic acid or methane-disulphonic acid.
  • R is other than hydrogen the comspasmolyflc acnvlty mt mews m Wtro pounds possess asymmetric carbon atoms and may exist
  • the rat uterus was prepared according to the method in optically active or racemic forms all of which forms described by Burn (Biological Standardisation, Oxford are comprised within the present invention. In such com- University Press, London, 1950 (page 177). The organ was stimulated, every 3 minutes, with oxytocine and BaCl at the final concentration of 2.1(H I.U./ml. and 1.10?
  • compositions comprising one or more compounds according to the invention in association with a pharmaceutical carrier or excipient.
  • compositions according to the invention may be adapted for oral, rectal or parental administration, advantageously in the form of dosage units, each dosage unit being adapted to supply a single dose of active ingredient.
  • the dosage units of the compositions according to the invention may for example take the form of tablets, dragees, capsules, suppositories or ampoules. Other convenient forms of compositions according to the invention include suspensions, syrups. etc.
  • the pharmaceutical carriers or excipients in the compositions may for example be those conventional in the art, for example tabletting excipients, capsule gelatin, suppository bases, water, edible oils, fiavouring, sweetening, odour-producing, suspending, dispersing or thickening agents and the like.
  • the free bases and acid addition salts according to the invention are preferably present in the dosage unit preparations in quantities of from 1 to 200 mg., advantageously 10 to 100 mg, per dosage unit.
  • compositions according to the invention are insoluble in water Whilst acid addition salts thereof, such as the hydrochloride, hydrobromide, sulphate and phosphate acid addition salts, are only very moderately soluble in water yielding aqueous solutions with low pH, for example of from 2 to 3.
  • acid addition salts thereof such as the hydrochloride, hydrobromide, sulphate and phosphate acid addition salts
  • aqueous solutions with low pH for example of from 2 to 3.
  • One advantageous form of compositions according to the invention comprises, therefore, one or more compounds according to the invention together with a solubility promotor.
  • Such compositions according to the invention may, for example be in the form of a solid mixture suitable for addition to distilled water to form an injectable solution or in the form of the injectable solution itself.
  • Solubility promoters are compounds which have the effect of increasing the solubility in water of sparingly soluble compounds and are in general well-known in the art.
  • One class of compounds which may conveniently be used as solubility promoters are compounds having a group, especially amides and derivatives thereof.
  • solubility promoters of this class which may be used in accordance with the invention are included metamizole (sodium 1 phenyl 2,3 dimethyl 5 pyrazolone 4- methylaminomethane sulphonate), urea, nicotinarnide, nicotinamide ascorbate, piperazine, urotropine .(hexamethylene-tetramine), antipyrene, acetamide, dimethylacetamide and coramine.
  • Particularly useful solubility promoters of this class include metamizole, nicotinamide and acetamine.
  • a second class of compounds which may conveniently be used as solubility promoters are compounds having a -OCH -CH(OH)CH OH group, especially 3-(substituted phenoxy)-1,2-propanediols.
  • compounds of this class include 3-(2-methoxy-phenoxy) -1,2-propanediol,
  • Particularly useful compounds of this class are 3-(2-methoxy-phenoxy) 1,2 propanediol and 3-(2-methoxy-4-propionyl-phenoxy)-1,2-propanediol.
  • injectable solutions prepared in this way in general have sufficient thermal stability to withstand the necessary sterilisation, whilst dilution of the solutions may result in the precipitation of the compounds according to the invention in an insoluble form.
  • solubility promoters may, according to the nature of the solubility promoters, also result in an increase in the pH of injectable solutions.
  • the ocmethyl-naphthylacetic acid diester of N,N'-di-(B-hydroxyethyl)-piperazine dihydrochloride has a solubility of 0.5% by weight yielding an aqueous solution having a pH of about 2.5, whilst the use of metamizole as solubility promoter makes possible the preparation of aqueous solutions containing 5% by Weight of the diester and having a pH of about 5.5.
  • Injectable solutions according to the invention containing solubility promoters may for example be prepared by addition of one or more compounds according to the invention (preferably in the form of acid addition salts e.g. dihydrochlorides) to an aqueous solution containing the solubility promoter.
  • the addition may be effected for example at room temperature with continuous stirring.
  • the solubility promoter is generally used in excess, for example four to fifty times the weight of the compound according to the invention.
  • the compounds according to the invention may be prepared by any convenient method, for example by reaction of a piperazine derivative of the formula with a l-naphthylacetic acid derivative of the formula (the group R being as defined above and X and Y representing groups able to react together to form divalent --OCH -CH radicals) and, if desired, conversion of the compound of Formula I thereby obtained into a monoor di-acid addition salt thereof.
  • the compounds are particularly advantageously prepared by any one of the following processes which constitute further features of the invention.
  • An acid halide, preferably the chloride, of an int-substituted or unsubstituted l-naphthyl acetic acid is reacted with N,N'-di-(fi-hydroxyethyl)-piperazi ne.
  • the reaction is preferably carried out in the presence of an acid-binding agent, such as an inorganic base, e.g. sodium or potassium carbonate or bicarbonate, or a tertiary amine such as pyridine, dimethylaniline, N-methylmorpholine etc., advantageously under substantially anhydrous conditions in an inert solvent medium.
  • an acid-binding agent such as an inorganic base, e.g. sodium or potassium carbonate or bicarbonate, or a tertiary amine such as pyridine, dimethylaniline, N-methylmorpholine etc.
  • Suitable solvents which may be used are hydrocarbon solvents such as benzene, xylene or toluene, ethers such as diethyl ether or dioxan, and inert liquid nitriles such as acetonitrile.
  • the reaction is conveniently effected under reflux at the boiling point of the solvent.
  • the acid halides of the l-naphthyl acetic acids used as starting materials are conveniently prepared by reacting the free acid with a halogenating agent, such as, e.g. thionyl chloride or phosphorus oxychloride.
  • a halogenating agent such as, e.g. thionyl chloride or phosphorus oxychloride.
  • a fi-haloethyl ester preferably the /3-chloroethyl ester of an a substituted or unsubstituted 1 naphthyl acetic acid is reacted with piperazine advantageously in the presence of a solvent.
  • An acid-binding agent may conveniently be present for example an inorganic base, such as an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate, e.g. sodium bicarbonate or potassium or calcium carbonate.
  • Suitable solvents which may be used include, for example, hydrocarbon solvents such as benzene or toluene, alcohols such as ethanol or methanol and ethers. The reaction is conveniently carried out under reflux at the boiling point of the solvent.
  • esters preferably alkyl esters of a-substituted or unsubstituted l-naphthyl acetic acids with N,N'-di-(;3-hydroxyethyl) piperazine, preferably in the presence of a transesterification catalyst such as an alkali metal hydroxide, amide etc. or strong organic or inorganic acids, e.g. sodium hydroxide or amide, ptoluene sulphonic acid or sulphuric acid.
  • the reaction is preferably carried out under substantially anhydrous conditions in a solvent medium, such as, for example, a hydrocarbon solvent e.g. benzene or toluene.
  • the alcohol which is formed during the reaction is preferably removed by distillation.
  • the esters of the u-substituted or unsubstituted l-naphthyl acetic acids are conveniently prepared f-rom the free acids by conventional methods of esterification.
  • An alkali metal salt, preferably the sodium salt, of an u-substituted or unsubstituted l-naphthyl acetic acid is reacted with an N,N-di-(fi-haloethyhpiperazine, preferably N,N-di- (fl-chloroethyl) piperazine, advantageously in the presence of a solvent medium such as, for example, an alcohol e.g. methanol, ethanol or iso-propanol, a hydrocarbon solvent such as benzene or toluene or an ether such as diethyl ether or dioxan.
  • a solvent medium such as, for example, an alcohol e.g. methanol, ethanol or iso-propanol, a hydrocarbon solvent such as benzene or toluene or an ether such as diethyl ether or dioxan.
  • EXAMPLE 1 (a) Preparation acid chlorides 0f a-substituted-I- naphthyl acetic acids.--l -g. of a-methyl-l-naphthylacetic acid were refluxed with 50 ml. of thionyl chloride during '3 hours. The excess thionyl chloride was removed under reduced pressure and the product was also isolated by distillation under reduced pressure. Yield: 15.6 g. (96%). The ot-methyl-l-naphthyl acetyl chloride boils at 120124 C./O. 1 mm.
  • EXAMPLE 3 18.5 g. of a-propyl-l-naphthylacetic acid, .100 ml. of methyl alcohol and 3 ml. of concentrated sulphuric acid were refluxed during 3 hours. After cooling the solution was concentrated under reduced pressure, poured into water and extracted with ether. Upon dis-tillation under reduced pressure 14.45 g. of vat-propyl-l-naphthylacetic acid methyl ester were obtained, boiling at 133-135" C./0.8 mm.
  • EXAMPLE 5 10 ml. of pyridine were added dropwise during 10 minutes into a solution of 10 g. ot-propyl-l-naphthylacetyl chloride and 3.5 g. of ethylene chlorohydrin in 50 ml. of
  • EXAMPLE '6 into moulds and allowed to cool.
  • Each suppositor contains Tablets: Formulation for the preparation of 1000 units. OOSO and respectlvely of awve Substance' G
  • EXAMPLE 10 a-Methyl-l-naphthylacetic acid diester of N,N'-di- (fi-hydroxyethyl)-piperazine dihydrochloride Lactose 150 Corn starch s 23
  • Magnesium stearate 2 Preparation: The active substance, exci'pients and half of the magnesium stearate are intimately mixed. The homogeneous mixture is then formed into pellets which are granulated. The remaining magnesium stearate is added to the granulate and pressed into convex tablets Weighing 200 mg. Each tablet contains 25 mg. of active substance.
  • Metamizole 1250 u-Methyl-l-naphthylacetic acid diester of N,N'-di- (,B-hydroxyethyl)-piperazine dihydrochloride 25 Bidistilled water, q.s. to 3 litre.
  • Vials are prepared by a method analogous to that described in Example 10. Each vial contains 25 mg. of active substance.
  • Vials are prepared from compositions A and -B respectively by a method analogous to that described in Example 10. Each vial contains 25 and 50 mg., respectively of active substance.
  • Acetamide 300 a-Methyl-l-naphthylacetic acid diester of N,N-di- (p-hydroxyethyl)-piperazine dihydrochloride .v 25
  • Vials are prepared by a method analogous to that described in Example 10. Each vial contains 25 mg. of active substance.
  • G a-Methyl-l-naphthylacetic acid diester of N,N'-di- (fl-hydroxyethyl) piperazine dihydrochloride 25 3 (2 methoxy-4-propionyl-phenoxy) 1,2propanediol 100 N,N-di-([3-hydroxyethyl)-piperazine Bidistilled water, q.s. to 1 litre.
  • the active substance is added to the solution obtained by dissolution of the 3-(2-methoxy-4-propionyl-phenoxy)- 1,2-propanediol in about three quarters of the indicated quantity of water.
  • the mixture is stirred until complete dissolution is achieved and then the pH of the solution is adjusted to 4 to 5 by addition of the N,N di-(;3-hydroxyethyD-piperazine.
  • the solution is made up to the required volume with the remainder of the water and poured into Vials which are then sealed and sterilised. Each vial contains 25 mg. of active substance.
  • Vials are prepared by a method analogeous to that described in Example 14.
  • R is straight-chained alkyl of from 1 to 3 carbon atoms.
  • R is alkyl of no more than 2 carbon atoms.
  • a compound as claimed in claim 1 which is an acid addition salt selected from the group consisting of a hydrochloride, hydrobromide, phosphate, sulphate, methanesulphonate, and methanedisulfonate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
US412859A 1964-04-28 1964-11-20 Esters of piperazine 1, 4-diethanol Expired - Lifetime US3338902A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB17604/64A GB1016968A (en) 1964-04-28 1964-04-28 Piperazine esters of ª‡-substituted 1-naphthylacetic acids

Publications (1)

Publication Number Publication Date
US3338902A true US3338902A (en) 1967-08-29

Family

ID=10098067

Family Applications (1)

Application Number Title Priority Date Filing Date
US412859A Expired - Lifetime US3338902A (en) 1964-04-28 1964-11-20 Esters of piperazine 1, 4-diethanol

Country Status (9)

Country Link
US (1) US3338902A (en, 2012)
AT (1) AT254197B (en, 2012)
BE (1) BE656442A (en, 2012)
BR (1) BR6464391D0 (en, 2012)
CH (1) CH448099A (en, 2012)
ES (1) ES306519A1 (en, 2012)
FR (1) FR4374M (en, 2012)
GB (1) GB1016968A (en, 2012)
IL (1) IL22496A (en, 2012)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2995554A (en) * 1958-09-08 1961-08-08 Lakeside Lab Inc Substituted glycolic acid esters of 1, 4-bis-(hydroxyalkyl)-piperazines
US2996506A (en) * 1961-08-15 Hcxchb

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996506A (en) * 1961-08-15 Hcxchb
US2995554A (en) * 1958-09-08 1961-08-08 Lakeside Lab Inc Substituted glycolic acid esters of 1, 4-bis-(hydroxyalkyl)-piperazines

Also Published As

Publication number Publication date
AT254197B (de) 1967-05-10
BE656442A (en, 2012) 1965-05-31
CH448099A (de) 1967-12-15
ES306519A1 (es) 1965-04-01
BR6464391D0 (pt) 1973-08-07
FR4374M (en, 2012) 1966-08-29
IL22496A (en) 1968-12-26
GB1016968A (en) 1966-01-12

Similar Documents

Publication Publication Date Title
US3078214A (en) Treatment of mental disturbances with esters of indoles
EP0198456B1 (en) 1,7-naphthyridine derivatives and medicinal preparations containing same
US3661921A (en) N-substituted and n,n - disubstituted aminocarbonylalkyl compounds and their production
US3388128A (en) Substituted 1, 4-diazabicyclo [4. 4. 9] decanes
US4249021A (en) Indanacetic acid compounds
US3407193A (en) Substituted biurets
US4229464A (en) Aminopropanol substituted indole compounds and compositions for the treatment of cardiac and circulatory diseases
US3843638A (en) 2,4-diamino-substituted pyrido(3,2-d)pyrimidines and salts thereof
US4221793A (en) N,N'-Disubstituted piperazine derivative
US3338902A (en) Esters of piperazine 1, 4-diethanol
US2561385A (en) Aranoalkyl-z-tmenyl-cycloalkenyl
US3290326A (en) Esters of 4-lower alkyl-5-oxazole-car-bamic acid and intermediates therefor
US4065451A (en) 1,3-Dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one, substituted diamino acetate esters and their acid salts
US4096259A (en) Non-amphetaminic psychostimulating compositions of 1,4-disubstituted piperazines
JPS60158190A (ja) ヒダントイン誘導体およびその製法ならびにそれを含有する医薬
US4656175A (en) Method of treating aggressive behavior and psychotic conditions employing 1-piperazinocarboxylates
US3081302A (en) Certain-p-acetaminophenoxyacetamido derivatives
CS219885B2 (en) Method of making the n-lallyl-2-pyrolidylmethyl/-2,3-dimethoxy-5-sulphamoylbenzamide
US4247705A (en) 4-Substituted 2-iminoimidazolidine compounds
US4333929A (en) Carboxamidine derivatives and hypoglycemical use
US4139621A (en) N-(4-substituted-3,5-dichloro-phenyl)-piperazines
US3331855A (en) Derivatives of reserpinediol and deserpidinediol
US4327107A (en) Method useful in the treatment of sugar cataracts using 4-substituted-2-iminoimidazolidine compounds
US3586675A (en) Fused thiazines
US4317832A (en) Indolyl and methylindolyl substituted aminoalkyl guanidines